Latest & greatest articles for alopecia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alopecia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alopecia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for alopecia

21. Naltrexone for Alopecia: Clinical Effectiveness

was identified regarding the clinical effectiveness of naltrexone for the treatment of alopecia. Tags alopecia, hair, naltrexone, other miscellaneous topics, hair loss, hairloss Files Rapid Response Reference List Published : August 8, 2016 Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter: (...) Naltrexone for Alopecia: Clinical Effectiveness Naltrexone for Alopecia: Clinical Effectiveness | CADTH.ca Find the information you need Naltrexone for Alopecia: Clinical Effectiveness Naltrexone for Alopecia: Clinical Effectiveness Published on: August 8, 2016 Project Number: RA0859-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical effectiveness of naltrexone for the treatment of alopecia? Key Message No literature

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

22. Alopecia in survivors of critical illness Full Text available with Trip Pro

Alopecia in survivors of critical illness 28979506 2018 11 13 1751-1437 17 3 2016 Aug Journal of the Intensive Care Society J Intensive Care Soc Alopecia in survivors of critical illness. 270 10.1177/1751143715626165 Battle Ceri E CE Critical Care Unit, Morriston Hospital, Swansea, UK. James Karen K Critical Care Unit, Morriston Hospital, Swansea, UK. Temblett Paul P Critical Care Unit, Morriston Hospital, Swansea, UK. eng Journal Article 2016 07 25 England J Intensive Care Soc 101538668 1751

2016 Journal of the Intensive Care Society

23. Drug-related hair loss: not only anti-cancer medication

Drug-related hair loss: not only anti-cancer medication Prescrire IN ENGLISH - Spotlight ''Drug-related hair loss: not only anti-cancer medication '', 1 May 2016 {1} {1} {1} | | > > > Drug-related hair loss: not only anti-cancer medication Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Drug-related hair loss: not only anti-cancer medication Hair (...) loss can sometimes have a profound psychological impact. It is linked to a wide range of causes, including medication, and not only anti-cancer drugs. Hair loss, both temporary and permanent, diffuse or localised, sudden or gradual, is a frequent cause for complaint. It can sometimes have a profound psychological impact. Hair loss is observed in a number of situations: hormonal disorders, dietary deficiency, auto-immune diseases, infections, inflammation, psychological or emotional trauma, tumours

2016 Prescrire

24. Traditional Anticoagulants and Hair Loss: A Role for Direct Oral Anticoagulants? A Review of the Literature Full Text available with Trip Pro

Traditional Anticoagulants and Hair Loss: A Role for Direct Oral Anticoagulants? A Review of the Literature Hair loss is associated with the anticoagulants heparin and warfarin. With the recent availability of direct oral anticoagulants (DOACs) it is of clinical interest to know if they are implicated with hair loss and/or whether they could be successfully prescribed for patients who suffer from coumarin- or heparin-related alopecia. Initially reports of heparin- and coumarin-associated (...) alopecia available through PubMed and Medline were explored in order to establish the cause of this side effect. Currently there is a lack of unanimity on why anticoagulants cause alopecia. However, timing and presentation strongly suggest that telogen effluvium is part of the process. The observation that both heparins and coumarins cause a similar pattern of hair loss suggests a shared mechanism related to anticoagulant activity. To date, the World Health Organization has received 405 reports of DOAC

2016 Drugs - real world outcomes

25. Alopecia, androgenetic - female

hairs similar to vellus hairs. The prevalence and severity of androgenetic alopecia in women increases greatly after the menopause and affects about a third of white women aged 70 years and older. Complications of androgenetic alopecia may include adverse psychosocial effects. Hair loss in women tends to progress over time, but the rate of progression is unpredictable. Women with androgenetic alopecia rarely go completely bald. The diagnosis is usually made from the history and clinical findings (...) months to a year. Women with androgenetic alopecia rarely go completely bald. [ ; ; ; ; ; ] Diagnosis Diagnosis of alopecia, androgenetic - female Diagnosis and assessment How should I assess a woman with hair loss in primary care? For a woman presenting with hair loss in primary care, the diagnosis of androgenetic alopecia is usually made from the history and clinical findings alone. Take a detailed history to assess the severity, impact, and possible causes of hair loss. Ask about the following

2016 NICE Clinical Knowledge Summaries

26. Drugs for male- and female-pattern baldness: Just a hair bit more effective than doing nothing?

care research. www.acfp.ca October 11, 2016 Drugs for male- and female-pattern baldness: Just a hair bit more effective than doing nothing? Clinical Question: What is the effect of approved medications for androgenic alopecia in men and women? Bottom-line: For men using finasteride or minoxidil, one in 4-8 more than placebo will notice at least slight improvement in hair count over 6-12 months, with no clear evidence one is better. For every 84 men taking finasteride for hair loss, one extra (...) outcome. o Minoxidil 1-5% versus placebo: ? Patient-rated moderate improvement or better (26% versus 14%, NNT=8) ? Increase in hair count, +13 hairs/cm 2 , at 6-12 months. Context: • Prevalence of androgenic alopecia increases with age, with approximately ½ of men and ? of women balding after age 70. 10 • Numerous other interventions (like nutritional supplements or Handi-Dome Comb) have low quality evidence with inconsistent results. 9,11 • Only minoxidil for women or men, and finasteride for men

2016 Tools for Practice

27. Hair micro transplant using follicular unit extraction technique for alopecia

Hair micro transplant using follicular unit extraction technique for alopecia Hair micro transplant using follicular unit extraction technique for alopecia Hair micro transplant using follicular unit extraction technique for alopecia Macchiavello D, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A, López A, Rey-Ares L., Hernandez Vásquez A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Macchiavello D, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A, López A, Rey-Ares L., Hernandez Vásquez A. Hair micro transplant using follicular unit extraction technique for alopecia. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rápida N° 444, Buenos Aires, Argentina

2015 Health Technology Assessment (HTA) Database.

28. Testing Vitamin B12 Levels in Neuropathy, Alopecia, Dizziness, and Fatigue: A Rapid Review

Testing Vitamin B12 Levels in Neuropathy, Alopecia, Dizziness, and Fatigue: A Rapid Review Testing vitamin B12 levels in neuropathy, alopecia, dizziness, and fatigue: a rapid review Testing vitamin B12 levels in neuropathy, alopecia, dizziness, and fatigue: a rapid review Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Health Quality Ontario. Testing vitamin B12 levels in neuropathy, alopecia, dizziness, and fatigue: a rapid review. Toronto: Health Quality Ontario (HQO). Rapid Review. 2014 Authors' objectives The objective of this analysis is to identify the clinical utility of testing vitamin B12 levels in cases of neuropathy, alopecia, dizziness, and fatigue. Authors' conclusions There is very low quality evidence that there is no association between vitamin B12 levels and neuropathy. There is very low

2014 Health Technology Assessment (HTA) Database.

29. British Association of Dermatologists' guidelines for the management of alopecia areata

and there is no known race or sex preponderance. Alopecia areata usually presents as patches of hair loss on the scalp but any hair-bearing skin can be involved. The affected skin may be slightly reddened but otherwise appears normal. Short broken hairs (exclamation mark hairs) are frequently seen around the margins of expanding patches of alopecia areata. The nails are involved in about 10% of patients referred for specialist advice. 6.1 Prognosis Hair follicles are preserved in alopecia areata and the po- tential (...) for recovery of hair growth is maintained, even in longstanding disease. One study from Japan reported that spontaneous remission within 1 year occurred in 80% of patients with a small number of circumscribed patches of hair loss. 3 Data from secondary and tertiary referral centres are less favourable indicating that 34–50% of patients will recover within 1 year. Almost all will experience more than one episode of the disease, and 14–25% progress to total loss of scalp hair (alopecia totalis, AT) or loss

2012 British Association of Dermatologists

30. How Do You Advise the Balding Patient?

with good occipital-parietal hair density. Given the myriad options, it is essential that the internist be able to offer advice and assist the balding patient in making an informed decision. Male pattern hair loss is medically referred to as androgenetic alopecia (AGA). At initial presentation, it is important to differentiate between AGA and other causes of hair loss. As with any condition, the past medical history can yield clues. Febrile infections, major surgery requiring general anesthesia, cancer (...) alopecia. The gold standard for the diagnosis of AGA is scalp biopsy, though this invasive procedure is rarely required.3 In men, the diagnosis of AGA is often easy: the hair loss is characterized by an em-shaped balding pattern, variably thinning strands, and the presence of vellus-like hair in place of terminal strands. In women not suffering from androgen excess, AGA is diagnosed in those presenting with diffuse thinning over the frontal region; the stereotypical male frontotemporal balding pattern

2010 Clinical Correlations

31. No evidence of effective treatments for alopecia

hair regrown during treatment will persist once treatment is finished. None of the studies asked participants to report their opinion of hair growth or whether their quality of life had improved with treatment. Context Alopecia areata is a condition that causes patchy hair loss. The size and number of patches and progress of the disease can vary between people. It can affect the entire scalp (alopecia totalis) or cause loss of all body hair (alopecia universalis). It is a relatively common (...) condition, affecting 0.15% of the population. Although in many cases it can be a self-limiting condition, nevertheless hair loss can often have a severe social and emotional impact. Cochrane Systematic Review Delamere FM et al. Interventions for alopecia areata. Cochrane Reviews 2008, Issue 1. Art. No.: CD004413. DOI:10.1002/14651858.CD004413.pub2. This review contains 17 studies involving 540 participants. Pearls No. 93, July 2008, written by Brian R McAvoy

2008 Cochrane PEARLS

32. Children of mothers with breast cancer were distressed by hair loss; those >10 years of age wanted more information about their mother’s condition

Children of mothers with breast cancer were distressed by hair loss; those >10 years of age wanted more information about their mother’s condition Children of mothers with breast cancer were distressed by hair loss; those >10 years of age wanted more information about their mother’s condition | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we (...) use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Children of mothers with breast cancer were distressed by hair loss; those >10 years of age wanted

2008 Evidence-Based Nursing

33. Scalp Cooling to Prevent Chemotherapy-Induced Hair Loss

in the prevention of docetaxel-induced alopecia. Eur J Cancer 1997;33(2):297-300. Edelstyn GA, MacDonald M, MacRae KD. Doxorubicin-induced hair loss and possible modification by scalp cooling. Lancet 1977;2(8031):253-4. Satterwhite B, Zimm S. The use of scalp hypothermia in the prevention of doxorubicin-induced hair loss. Cancer 1984;54(1):34-7. Kennedy M, Packard R, Grant M, Padilla G, Presant C, Chillar R. The effects of using Chemocap on occurrence of chemotherapy-induced alopecia. Oncol Nurs Forum 1983;10(1 (...) ):19-24. Parker R. The effectiveness of scalp hypothermia in preventing cyclophosphamide-induced alopecia. Oncol Nurs Forum 1987;14(6):49-53. Giaccone G, Di Giulio F, Morandini MP, Calciati A. Scalp hypothermia in the prevention of doxorubicin-induced hair loss. Cancer Nurs 1988;11(3):170-3. Macduff C, Mackenzie T, Hutcheon A, Melville L, Archibald H. The effectiveness of scalp cooling in preventing alopecia for patients receiving epirubicin and docetaxel. Eur J Cancer Care (Engl) 2003;12(2):154-61

2005 Swedish Council on Technology Assessement

34. Direct To Consumer Advertising: Finasteride for male pattern hair loss

in this situation? Let’s explore the issue using one of the products most advertised to consumers, a drug for male pattern hair loss, finasteride (Propecia ® ). What questions should you answer before writing a prescription? Does this patient fit the drug’s indications? Propecia ® is for a cosmetic effect in young men (18-41 yrs) who have mild to moderate scalp hair loss of the vertex or anterior mid scalp. It does not benefit men with hair loss at the temples or those who are completely bald (...) of hair loss. N Engl J Med. 1999; 341:964-973. Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol. 2000; 43:768-76. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998; 39:578-89. Roberts JL, Fiedler V, Imperato-McGinley J, et al. Clinical dose ranging studies with finasteride, a type 2

2001 Therapeutics Letter